Viridian Therapeutics Inc Dossier - Source-backed chat

Viridian Therapeutics Inc

VRDNNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)0.96

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $20.59Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $2.3B

Enterprise Value $2.2B

Shares Outstanding 113.3M diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Viridian Therapeutics is positioned for a transformational year in 2026, transitioning from a clinical-stage biotech to a commercial-stage entity. The company's lead candidate, veligrotug (IV anti-IGF-1R), has a PDUFA target action date of June 30, 2026, under Priority Review. Additionally, its subcutaneous candidate, elegrobart (VRDN-003), recently delivered positive Phase 3 results in both active and chronic thyroid eye disease (TED), setting up a BLA submission in Q1 2027. Backed by a robust cash position of $762.2 million as of March 31, 2026, Viridian is well-funded to execute its commercial launch and advance its pipeline of FcRn and TSHR inhibitors.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets16 analysts · as of 18 Aug 2026

Low · most bearish analyst$22.00

Mean target$36.63

High · most bullish analyst$50.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$22.00

Veligrotug faces regulatory delays or a Complete Response Letter (CRL) from the FDA, pushing back the commercial timeline. Commercial adoption of veligrotug is slower than expected due to intense competition from Amgen's established Tepezza franchise and its incoming subcutaneous formulation. High commercial launch expenses accelerate cash burn, necessitating dilutive equity raises.

Base CaseCentral scenario

$36.63

Matches the consensus mean

Veligrotug is approved by the FDA by the June 30, 2026 PDUFA date, and Viridian initiates its commercial launch. Elegrobart's BLA is successfully submitted in Q1 2027. The company's cash runway remains sufficient to fund operations into 2027, allowing it to reach key commercial and clinical milestones without immediate dilutive financing.

Bull CaseUpside scenario

$50.00

Veligrotug receives FDA approval on or before June 30, 2026, with a clean safety label, enabling a highly successful independent U.S. launch. Elegrobart's subcutaneous autoinjector profile is widely adopted as a more convenient alternative to Amgen's Tepezza, capturing significant market share in both active and chronic TED. Pipeline programs (VRDN-008 and TSHR) deliver strong early-stage data, validating Viridian's broader autoimmune platform.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Near-term commercial catalyst with veligrotug's PDUFA date on June 30, 2026.
Differentiated subcutaneous candidate (elegrobart) with positive Phase 3 data, offering superior patient convenience over existing IV therapies.
Strong balance sheet with $762.2 million in cash, cash equivalents, and marketable securities as of March 31, 2026.
Expanding pipeline targeting validated pathways in autoimmune and rare diseases, including FcRn and TSHR programs.

Key Investment Risks

Commercial execution risk as an independent launcher competing against Amgen's established Tepezza.
Regulatory risks associated with FDA approval timelines and potential labeling restrictions.
High cash burn rate driven by preparatory commercial activities and clinical trials.
Potential shareholder dilution from future capital raises or convertible debt conversions.

Thesis Invalidation Triggers

FDA issuance of a Complete Response Letter (CRL) for veligrotug.
Significant safety signals or adverse events emerging during the commercial launch of veligrotug or clinical development of elegrobart.
Failure to submit the elegrobart BLA in Q1 2027.
Rapid depletion of cash reserves leading to premature dilutive financing.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.